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Abstract
Background: Attention deficit hyperactivity disorder (ADHD) is among the most common psychiatric disorders of
childhood that persists into adulthood in the majority of cases. The evidence on persistence poses several
difficulties for adult psychiatry considering the lack of expertise for diagnostic assessment, limited treatment
options and patient facilities across Europe.
Methods: The European Network Adult ADHD, founded in 2003, aims to increase awareness of this disorder and
improve knowledge and patient care for adults with ADHD across Europe. This Consensus Statement is one of the
actions taken by the European Network Adult ADHD in order to support the clinician with research evidence and
clinical experience from 18 European countries in which ADHD in adults is recognised and treated.
Results: Besides information on the genetics and neurobiology of ADHD, three major questions are addressed in
this statement: (1) What is the clinical picture of ADHD in adults? (2) How can ADHD in adults be properly
diagnosed? (3) How should ADHD in adults be effectively treated?
Conclusions: ADHD often presents as an impairing lifelong condition in adults, yet it is currently underdiagnosed
and treated in many European countries, leading to ineffective treatment and higher costs of illness. Expertise in
diagnostic assessment and treatment of ADHD in adults must increase in psychiatry. Instruments for screening and
diagnosis of ADHD in adults are available and appropriate treatments exist, although more research is needed in
this age group.
Review
The European Network Adult ADHD
The European Network Adult ADHD was founded in
2003 and includes 40 professionals from 18 countries
across Europe with an interest in and experience of
ADHD in adults http://www.adult-adhd.net. This inde-
pendent expert panel was set up to help improve the
diagnosis and management of ADHD in adults through-
out Europe. It is the opinion of the panel that today,
due to lack of recognition and misunderstanding about
the disorder and the use of appropriate, stimulant or
non-stimulant medication, to control symptoms of
ADHD, many adults with ADHD are misdiagnosed and
are often prevented from receiving effective treatments.
This may lead to unnecessary suffering for individual
patients, their families and work colleagues.
Objectives of consensus statement
The objectives of this consensus statement are to
increase awareness of the following: (1) That ADHD
often presents as an impairing lifelong condition in
adults, yet is currently underdiagnosed and treated in
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many European countries; (2) That instruments for
screening and diagnosis of ADHD in adults are avail-
able; (3) That appropriate treatments exist.
Three major questions are addressed in this statement:
(1) What is the clinical picture of ADHD in adults? (2)
How can ADHD in adults be properly diagnosed? (3)
How should ADHD in adults be effectively treated?
Methodology
This document is the result of three meetings between
2003 and 2009 in which the need for communication
and a consensus statement in Europe were identified.
A formally prepared document with consensus state-
ments agreed by experts within the group was
reviewed and discussed. Following this process the
final document was circulated for written approval by
all members of the European Network. For the assem-
bly of the document, reviews and randomised con-
trolled trials in adults were identified from Medline,
Embase and the Cochrane Database, as well as from
reviews on ADHD in children and cross-referencing
and identification by the participating experts. Details
of the clinical presentation of adults with ADHD were
further informed by clinical expertise. This consensus
statement is written for specialists in psychiatry but is
also intended to increase the understanding of the dis-
order and to facilitate referral for diagnosis, treatment
and follow-up from primary health care physicians and
other health care providers.
Background
ADHD is among the most common psychiatric disor-
ders in childhood with well established diagnostic and
treatment services available throughout most of Europe.
Until recently, the disorder was considered by many to
resolve during adolescence and young adulthood with
little or no continued impact in adult life [1], although
descriptions of the adult condition appeared in the psy-
chiatric literature from 1976 onwards [2]. However cur-
rent evidence indicates that in the majority of cases
ADHD persists into adult life where it is associated with
a range of clinical and psychosocial impairments.
Numerous follow-up studies of children with ADHD
show that the disorder persists during adolescence and
adulthood in around two-thirds of individuals [3-11]
either as the full blown disorder or in ‘partial remission’
with persistence of some symptoms associated with con-
tinued clinical and psychosocial impairments. In the
meta-analysis of these data from Faraone and colleagues
it was concluded that about 15% retain the full diagnosis
by age 25 years, with a further 50% in partial remission
[12], indicating that around two-thirds of children with
ADHD continue to have impairing levels of ADHD
symptoms as adults.
Although in some cases the symptoms of ADHD may
appear to diminish during adolescence, this may not be
the case relative to controls and does not mean that
functioning is unimpaired. In a follow-up study of 119
boys of 19 years of age with childhood onset ADHD,
symptom levels seemed to be lower than in childhood
but 90% still did not function well [13]. Importantly,
although symptoms levels appear to reduce as people
grow older there are parallel changes among control
groups; so that significant case-control differences are
retained [14].
In a study from the World Health Organisation Men-
tal Health Survey, it was found that childhood predictors
of adult ADHD included the combined subtype of
ADHD in childhood, symptom severity, the presence of
comorbid depression, high rates of other comorbidities,
social adversity and parental psychopathology [3]; while
Biederman had previously reported family history of
ADHD, psychosocial adversity and comorbidity with
conduct, mood and anxiety disorders to be predictors of
persistence [15]. Nevertheless, all forms of ADHD are
known to persist into adulthood including ADHD with
predominantly inattentive symptoms and ADHD asso-
ciated with milder levels of impairment and
comorbidity.
The prevalence of ADHD in adults estimated from
epidemiological studies is in the range of 2-5% [16-19].
Persistent forms of ADHD are thought to have a higher
familial loading than ADHD that does not persist, with
increased rates of ADHD among the parents and sib-
lings of those with persistent ADHD and high rates of
ADHD among the offspring of parents with ADHD [20].
Twin and adoption studies indicate that the familiality
of ADHD symptoms results from genetic factors rather
than shared environmental risks, providing a further
rationale for considering ADHD as a lifetime condition
[21]. ADHD occurs in around 10-20% of people with
common mental health problems according to epide-
miological and clinical research [22-27]. Further studies
show that this rate may be higher in some clinical popu-
lations such as those attending forensic, addiction and
personality disorder clinics, highlighting the importance
of screening within such high risk populations [28].
There is growing recognition of the importance of
diagnosing and treating the disorder in parents of chil-
dren with ADHD [29] since around 20% of parents of
children with ADHD will have ADHD themselves [30].
Furthermore, parents with ADHD may have difficulty in
implementing parent training strategies for the treat-
ment of behavioural problems in their offspring. Since
the recognition of ADHD is relatively recent throughout
much of Europe there are in addition many adults with
ADHD who were never diagnosed or treated for ADHD
when they were children [31]. Recent national guidelines
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now recommend that ADHD should be recognised and
appropriately treated throughout the lifespan [32-34].
Despite this, across much of Europe many professionals
working in adult mental health services remain unaware
that ADHD frequently persists into adult life and remain
uninformed about the clinical presentation and the con-
sequences of ADHD across the lifespan.
Another reason for underdiagnosis and treatment of
ADHD in adults is the age-dependent change in the
presentation of ADHD symptoms. The more overtly
impairing symptoms in childhood, hyperactivity and
impulsivity, often become less obvious in adulthood,
shifting the problem to more subtle symptoms such as
inner restlessness, inattention, disorganisation and to
impairment in behaviours related to executive function-
ing; and this may lead to discontinuation of treatment
when they are still required [13,31,35-39]. Additional
reasons for underdiagnosis of ADHD include the fre-
quent presence of comorbid psychiatric syndromes,
which in clinical practice may be identified as the pri-
mary or only diagnosis. Finally, stigma and myths con-
tinue to surround the condition and its treatment,
particularly with stimulant medication [40,41].
Stigma in general and among professionals
ADHD is an established disorder in childhood with
child and adolescent mental health or paediatric ser-
vices for ADHD available across most of Europe. Yet
adult services for people with ADHD remain relatively
scarce despite strong evidence for the benefits of diag-
nosing and treating ADHD in adults (reviewed in
[32]). There are still many professionals that are
unsure of the diagnosis and the appropriate use of
ADHD medications in adult mental health. Some con-
tinue to express fears about treating a ‘non-existent
disease’ or causing drug addiction with stimulant med-
ication, despite evidence to the contrary [42]. The rea-
sons for this are likely to be based on the historical
perception of ADHD as a disorder that is restricted to
childhood and the continued presence of stigma and
clinical mythology that surrounds the disorder and its
treatment; and the traditional separation of adult from
child psychiatry. What is clear is that there remains a
gulf in the perception of the disorder between those
working in paediatric and child and adolescent mental
health services and those working in adult mental
health, that cannot be explained on the basis of vali-
dated evidence based information [43].
Stigma related to the term ADHD is one component
of the problem that nearly always arises in the context
of lack of awareness or understanding of available data.
Within the mental health profession stigma is further
associated with the restricted regulatory status in many
countries for most of the medications that treat ADHD
in adults, but has other reasons as well. ADHD in adults
remains a disorder which is poorly understood and
where an ‘emotional burden’ is attached to the term
especially among professionals who have not tradition-
ally been involved in the diagnosis or treatment of
ADHD [42,44,45]. People suffering from ADHD are
often stereotyped as lazy, bad or aggressive, or consid-
ered to have a behavioural or special needs problem
rather than a mental health disorder that requires treat-
ment [44]. The diagnosis may also be overlooked
because ADHD is a highly symptomatic disorder and
those less familiar with the onset, course, psychopathol-
ogy and comorbidities associated with the disorder may
mistake ADHD for other common mental health pro-
blems such as mood or personality disorders.
While increasing awareness and availability of accurate
information is a high priority, many education programs
for primary care physicians lack a component for
ADHD so that a high percentage remain unaware of the
way that ADHD affects people beyond the childhood
years [45]. Furthermore, education about adult ADHD
has not been included in most college programs for
medical and psychology students, as well as training of
professionals in adult mental health. Education pro-
grams therefore need to target all stages of professional
development, from students through to primary and
secondary care physicians and psychologists, to ensure
appropriate early recognition, diagnosis and treatment
are provided. Referral to specialist clinics should be pos-
sible where secondary care physicians lack sufficient
training for more complex cases.
In terms of treatment, stimulants are by far the best
studied and most effective treatment for ADHD across
the lifespan, yet their use in some parts of Europe
remains controversial in children and more widely
across Europe in adults. The recent National Institute
for Health and Clinical Excellence (NICE) guidelines
from the UK describes the situation in which a drug
treatment is considered safe to give to children but not
safe to give to adults as an “anomaly” [32]. The NICE
guidelines have been pivotal in the UK by providing
national guidance for the development of clinical ser-
vices for adults with ADHD and the recommendation of
stimulants as the usual first line treatment. As a conse-
quence many new clinics are being established and
increasing numbers of adults are provided with effective
treatment in the form of stimulants, despite the lack of
formal recognition by regulatory bodies for use of medi-
cines. The current lack of licensed indications for the
use of stimulants in adults in most European countries
(but not in the US) is not supported by available data,
but rather results from the historical focus on ADHD as
a child disorder, commercial considerations by pharma-
ceutical companies and caution from regulators: a
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situation that may be revised in the next 1-2 years in
Europe as several formulations of methylphenidate and
dexamphetamine are being put forward for registration.
However, a recent safety review of the use of methyl-
phenidate from the European Medicines Agency, which
restricts its recommendation to children over 6 years of
age and adolescents and does not mention use in adults,
has led to methylphenidate no longer being licensed for
use in countries such as Norway.
Genes, environment and neurobiology
Family, twin and adoption studies show that ADHD is a
familial disorder with high heritability, indicating that a
significant genetic component influences risk for the
disorder [46-54]. Environmental factors are also likely to
play a role either as main causal factors in a few cases
[55] or by interaction with genetic risks.
Family studies indicate a risk to first degree relatives
of 4 to 10 fold the population rate, with prevalence
among first degree relatives in the range of 20-50% [20].
Data from numerous twin studies of parent and teacher
rated ADHD in children and adolescents indicate an
average heritability (the variance explained by additive
genetic factors) of around 76% [56], indicating that
familial influences on ADHD are largely genetic.
Furthermore twin studies that have investigated the con-
tinuity of ADHD at various developmental stages indi-
cate that continuity of symptoms across the lifespan is
largely the result of shared genetic effects [57-59]. Yet,
studies of self-rated ADHD symptoms in adult popula-
tion twin samples consistently report lower estimates of
heritability, in the region of 30-40% from two published
[59,60] and one unpublished (Larsson et al., in prepara-
tion) study. The reasons for the lower heritability has
not been fully investigated, but is likely to arise from the
use of self-rating ADHD scales in population twin sam-
ples for two main reasons. First there may be a variable
level of awareness among individuals when self-rating
their own ADHD symptoms, leading to inaccurate
ADHD symptom scores; and secondly self-ratings of
ADHD symptoms may be confounded by adult onset
conditions that generate ADHD-like symptoms, such as
anxiety, depression, fatigue and drug and alcohol use.
There is however as yet no empirical data to resolve
these questions, so we have to conclude that further
work is needed to fully understand the extent of genetic
influences on ADHD in adults.
Molecular genetic studies in adults are relatively
recent but are expected to confirm some genetic asso-
ciations identified in childhood ADHD samples and find
other genes that relate to persistence or remission of
ADHD symptoms in adult life. There is a great deal of
interest in the mechanisms by which the disorder per-
sists in some individuals and remits in others, since this
may identify new targets that prevent progression of the
disorder into adult life. One potential mechanism is
suggested by the developmental hypothesis of Jeffrey
Halperin, which proposed that ADHD is linked to an
early-appearing and enduring subcortical dysfunction
(weak arousal mechanisms), while symptom remission is
dependent on the extent of maturational changes in
executive control [61,62]. The emphasis is on the inter-
action between these two processes, with remission or
persistence of ADHD symptoms related to the emerging
balance between cortical and sub-cortical function.
Whether the processes involved can be neatly separated
into sub-cortical versus cortical is uncertain and
requires further detailed investigations, however a recent
large international study obtained evidence that the
same two processes account for 85% and 12% respec-
tively, of the genetic influences on ADHD [63].
Molecular genetic studies of ADHD in children pro-
vide direct support for the association of specific genes
with ADHD. Genetic variants within or near to the D4
(DRD4) and D5 (DRD5) dopamine receptor genes pro-
vide the most consistent findings supported by meta-
analysis [64]. Numerous other studies find evidence of
association with the dopamine transporter gene (DAT1),
the dopamine beta-hydroxylase gene (DBH), the seroto-
nergic transporter (5-HTT), the serotonergic receptor
(HTR1B), and the synaptosomal-associated protein, 25
kDa (SNAP-25) [48]. Taken together these candidate
gene findings are thought to explain around 3.2% of the
variance in ADHD symptoms in children [65]. More
recently whole genome association studies have identi-
fied novel genes such as CDH13 (a Cadherin gene) as
potential risk factors [66] and rare copy number variants
that confer higher risks in the order of odds ratios of 2-
5, depending on general cognitive ability (Williams et
al., reported at the World Congress of Psychiatric
Genetics, 2009).
Molecular genetic studies have also turned to the
study of ADHD in adults in recent years. Much of the
current research coordinated in Europe by Barbara
Franke from the Netherlands for the International Mul-
ticentre Persistent ADHD Collaboration (IMPACT)
group. This collaboration has successfully generated a
multi-site sample of around 3,000 patients and is conti-
nuing to develop. To date several publications highlight
potential associations with ADHD in adults, some but
not all of which are shared with genetic association find-
ings in children [67-72].
Environmental factors are also associated with ADHD
[73], particularly prenatal risk factors such as exposure
to alcohol, nicotine, drugs, high blood pressure and
maternal stress during pregnancy, as well as preterm
birth and low birth weight [74-76]. Evidence from
Romanian adoptees also suggests that severe early
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deprivation is causally related to ADHD [55]. In some
cases the environmental measure may be mediated by
genetic effects and may not always implicate environ-
mental exposure as the primary causal factor. For exam-
ple there is new evidence that prenatal exposure to
nicotine may reflect genetic effects rather than the direct
toxic effects of nicotine or other constituents of tobacco
smoke [77]. Overall it is likely that environmental risk
factors play an important role in the aetiology of ADHD
and that in many cases the impact of the environment
will be modified by genetic factors.
Neurocognitive, neurophysiological and neuroimaging
studies suggest that brain dysfunctions are involved in
the central components of the syndrome in children and
adults [78-82]. Fronto-striatal dysfunction and increased
dopamine transporter density in the striatum have both
been reported [83-86] although the finding of increased
dopamine transporter density remains a controversial
finding, perhaps secondary to drug treatments for
ADHD [87,88]. Magnetic resonance imaging (MRI) stu-
dies indicate smaller volumes of caudate, corpus callo-
sum, cerebellum and right frontal areas, as well as
increased cortical thinning [89-97]. Functional MRI data
show differences in brain functioning between ADHD
and controls including some studies of drug naïve
patients [91,98-103]. Positron emission tomography
(PET) shows abnormal cerebral glucose metabolism in
prefrontal and premotor areas of the frontal lobe in
ADHD adults [104-106]. In addition single photon emis-
sion computed tomography studies show studies show
hypoperfusion and hypofunctioning of prefrontal and
striatal regions in children and older adults with ADHD
compared to controls [107,108]. The immediate and
marked response of ADHD symptoms to stimulant
medications such as amphetamines and methylpheni-
date, which increase levels of synaptic dopamine, sug-
gests that the main underlying pathophysiological
process may involve deficits or imbalances in catechola-
minergic, dopaminergic, and nicotinergic functioning
[109-111].
Clinical Picture of ADHD in adults
Definition of ADHD
The two most frequently used diagnostic terms to
describe the condition in childhood are attention-defi-
cit/hyperactivity disorder (ADHD) and hyperkinetic dis-
order (HKD). For both definitions the disorder is
defined as a clinical syndrome characterised by the pre-
sence of developmentally inappropriate levels of inatten-
tion, hyperactivity and impulsivity, starting in childhood
and leading to impairment. The Diagnostic and Statisti-
cal Manual of Mental Disorders (DSM-IV) criteria for
ADHD as defined by the American Psychiatric Associa-
tion are the most widely used criteria and describe three
subtypes of ADHD based on the predominant symptom
pattern: inattentive type, hyperactive-impulsive type and
the combined type [112]. The International Classifica-
tion of Diseases (ICD-10) criteria for HKD as defined by
the World Health Organisation (WHO) are more con-
servative and define a severe subgroup of people fulfill-
ing the ADHD combined type diagnosis [113]. This
results in a lower estimated prevalence of HKD (about
1%) compared to the prevalence estimates of 4-8% for
ADHD in childhood [114]. ICD-10 criteria also exclude
the presence of common co-occurring disorders includ-
ing anxiety or depression [115] that are allowed under
the DSM-IV definition of ADHD.
The next edition of the DSM (version 5) now in pre-
paration is due to be published in 2013 and the revised
ICD (version 11) for 2015. The revised DSMV criteria
are expected to follow similar lines to the current cri-
teria with the following expected changes http://www.
dsm5.org:
(1) Symptom thresholds: For older adolescents and
adults (aged 17 and above) only 4 symptoms in
either the inattentive or hyperactive-impulsive
domain are required.
(2) The list of hyperactive-impulsive symptoms has
been increased to 13 to include ‘uncomfortable
doing things slowly or carefully’, ‘is often impatient’,
‘difficult to resist temptations or opportunities’ and
‘tends to act without thinking’.
(3) Descriptions of symptom items have been elabo-
rated to include more specific descriptions of beha-
viour, some of which are more applicable to adults.
(4) The age of onset criteria has been broadened to
include ‘noticeable inattentive or hyperactive-impul-
sive symptoms by the age of 12 years’.
(5) The requirement for clear evidence of impair-
ment from the symptoms is a key part of the diag-
nostic criteria, but is no longer required before the
age of 12 years or younger.
(6) Autism spectrum disorder is no longer listed as
an exclusion criterion.
These changes recognise that impairment from the
symptoms of ADHD may develop later in life and that
in some cases symptoms cannot be clearly identified
until the early adolescent years. The reduction in the
symptom threshold for adults as compared to children
recognises the age-dependent changes in the course of
the disorder, since the lower threshold in adults is still
clinically significant where there is clear evidence of
impairment from the symptoms of ADHD; and better
reflects the characteristics and natural course of the dis-
order. These changes mean that many people who pre-
viously met the ‘in partial remission criteria’ will meet
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full criteria for ADHD under the revised DSM-V (see
below for further discussion).
Clinical presentation in adults
Whereas the core symptoms of hyperactivity, impulsivity
and inattention, are well characterised in children, these
symptoms may have different and more subtle expres-
sions in adult life. Comparison with the normal beha-
viour of age, gender and cognitive ability matched
groups must be taken into account. For instance, where
children with ADHD may run and climb excessively, or
have difficulty in playing or engaging quietly in leisure
activities, adults with ADHD are more likely to experi-
ence inner restlessness, inability to relax, or over talka-
tiveness. Hyperactivity may also be expressed as
excessive fidgeting, the inability to sit still for long in
situations when sitting is expected (at the table, in the
movie, in church or at symposia), or being on the go all
the time. Impulsivity may be expressed as impatience,
acting without thinking, spending impulsively, starting
new jobs and relationships on impulse, and sensation
seeking behaviours. Inattention often presents as dis-
tractibility, disorganization, being late, being bored, need
for variation, difficulty making decisions, lack of over-
view, and sensitivity to stress. In addition, many adults
with ADHD experience lifetime mood lability with fre-
quent highs and lows, and short-fuse temper outburst
[35,37,116-118]. Typically, adults with ADHD will not
settle after the age of 30 but continue to change and/or
lose jobs and relationships, either through boredom or
being fired. They are usually underachievers with an
estimated annual twenty two days of excess lost role
performance [119-122]. As a consequence relationships
and jobs are often short lived. Relationships that last are
often impaired due to the inability to listen with con-
centration to the spouse, not finishing or procrastinating
tasks, often being on a ‘short fuse’ and interrupting con-
versations [123]. Driving accidents are increased in
young adults with ADHD as a result of being distracted,
impulsive and having an increased need for stimulation
[124-127]. ADHD patients are also more likely to be
subjected to other accidents like dog-bites and burns,
and display an unhealthy lifestyle: smoking, alcohol and
drug abuse, riskier sexual lifestyle, a delayed rhythm due
to chronic sleep problems, lack of structure and inap-
propriate healthcare [128-132]. Criminality in adulthood
is predicted by ADHD and comorbid conduct disorder
in childhood, especially with substance abuse and anti-
social personality disorder in adulthood. Among male
prisoners, ADHD was found to be strongly related to
the number of critical incidents involving aggression
and poorly controlled behaviour even after controlling
for the presence of antisocial personality disorder [133].
ADHD patients are significantly more arrested,
convicted, and incarcerated compared to normal con-
trols, and ADHD is increasingly diagnosed in adults in
forensic psychiatry [134-137].
An additional burden on family life may be the pre-
sence of one or more children with ADHD, which hap-
pens frequently due to the high familial risks of the
disorder. Adults with ADHD are at risk for poorer par-
ent-child relationships [138]. Inattention problems often
lead to inability to complete independent academic
work, resulting in underachievement at school, during
study and in the workplace compared to their peer
group with equivalent cognitive ability. Therefore many
have lower financial resources [17,18,139-141]. Many
feel isolated and lonely due to social handicaps and
shame about failures. They may have less success with
personal growth, lower ability to present themselves in a
socially appropriate fashion and lower mental and physi-
cal well-being, even in the presence of a high IQ
[8,121,142-144].
The clinical picture of ADHD is also coloured by fre-
quent co-morbidity. In childhood, as many as 65% of
children with ADHD have one or more co-morbid con-
ditions, including oppositional defiant and conduct dis-
order, anxiety and mood disorders, tics or Tourette
syndrome, learning disorders and pervasive developmen-
tal disorders (e.g. autism) [145-147]. Similarly in adults,
co-morbidity is the rule, with 75% of clinical patients
having at least one other disorder, and the mean num-
ber of psychiatric comorbidities being three [41,148].
Mood, anxiety, sleep, personality and substance use dis-
orders are found, as well as learning and other neurode-
velopmental disorders [22,37,41,121,144,148-152].
ADHD has also been associated with earlier onset of
substance abuse [153]. In adults with ADHD, gambling
and other addictions are very common [27,154-158].
Gender issues
As boys dominate clinical samples of ADHD in child-
hood, female manifestations and gender differences have
been relatively neglected in research as well as clinical
practice [159-162]. In childhood ADHD is identified far
more frequently in boys than girls with around a one in
five ratio in most studies. However, the differences in
prevalence and diagnostic rates according to gender
become far less skewed with age, as more females are
identified and become diagnosed in adulthood
[17,161,163,164]; and in some adult clinical series female
cases may predominate.
Several factors may explain these observations. In
childhood, girls may have less externalizing problems
than boys: they suffer more from internalizing problems,
chronic fatigue and inattention while boys may be more
hyperactive and more aggressive [165,166]. Girls show
lower rates of hyperactivity and comorbid conduct
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disorder than males, and more frequently have the inat-
tentive subtype of ADHD, with a later onset of impair-
ment [162,167]. For these reasons, general practitioners
and health care professionals are less aware of ADHD in
girls and they are thus less likely to be referred for treat-
ment [168]. In adulthood, the higher prevalence of anxi-
ety and depressive disorders in women may conceal
underlying ADHD and influence diagnosis and treat-
ment. As more women seek help from psychiatrists than
men, the change in referral pattern may also contribute
to the change in gender ratio within clinical populations
[169].
How can ADHD in adults be properly diagnosed?
Application of clinical criteria
Assessment starts with self-reported symptoms. The
physician should perform an in depth diagnostic inter-
view to look for the characteristic psychopathology by
careful questioning about childhood and current beha-
vioural symptoms. Although the patient appears to be
the best informant, comparison with parent and partner
reports in order to provide more information on severity
and pervasiveness of symptoms, is desirable [170]. Both
DSM-IV and ICD-10 criteria recognise that symptoms
of ADHD and HKD persist beyond childhood into
adulthood, yet neither set of criteria takes account of
age-dependent changes in terms of the number and
severity of symptoms, or changes in the way that the
symptoms of ADHD might present in adults. Rather,
they stipulate the exact same criteria as that applied in
children. However developmental changes occur that
include an increasing role for inattention and other
‘executive function’ difficulties in the impairments
related to the demands of adult life [171]. The DSM-IV
criteria suggest that adults who demonstrate only some
of the symptoms of ADHD should be given a diagnosis
of “ADHD, in partial remission”. This diagnosis, how-
ever, seems to underplay the significance of impairments
seen in adults who no longer meeting the full DSM-IV
criteria but show persistence of some impairing symp-
toms from childhood. In other words adults seem to
outgrow the criteria rather than the disorder.
We therefore conclude that a definition of remission
based on the number of criteria that have to be met in
childhood does not seem appropriate in clinical practice
with adults, especially as symptoms described by both
DSM-IV and ICD-10 criteria typically apply to children
and are not adjusted for developmental age
[13,35,172,173]. Furthermore, restriction of the diagnosis
to ICD-10 criteria that focused on a severe form of the
combined subtype during childhood will lead to under-
diagnosis of adults impaired by ADHD symptoms, espe-
cially in women. Symptoms of ADHD in adults should
therefore be judged with reference to developmentally
appropriate norms. Preliminary research suggests that
using the current DSM-IV criteria that stipulate six of
nine symptoms of either inattention or hyperactivity-
impulsivity, a lower threshold of four of nine of these
symptoms in either domain is sufficient to identify
impairing levels of ADHD symptoms in adults [17,174].
We therefore recommend that future criteria for ADHD
are appropriately adjusted by taking into account age-
related changes to symptoms and their relationship to
impairment.
Further work is now required to clarify whether
broadening the criteria to include those with four or
more symptoms in either domain is sufficiently specific
within adult mental health populations, since by lower-
ing the threshold other acute psychiatric disorders may
generate ADHD-like symptoms that reach this lower
threshold. This is however mainly a problem for cross-
sectional screening for ADHD, since in clinical practice
the diagnosis is based on eliciting a history of ADHD
symptoms that start in childhood or early adolescence
and are persistent (trait-like) and impairing over time
and can therefore be differentiated from adult onset dis-
orders. The other approach under investigation is the
identification of alternative descriptions of behavioural
impairments seen in adults with ADHD, such as the
ecological executive function deficits described by sev-
eral authors in recent years [175,176], which may show
greater sensitivity and specificity for the diagnosis in
adults.
As discussed, the expression of ADHD in adults is to
some extent different from that in children and the
diagnostic descriptions of some of the features need to
be adapted to adult expressions of the disorder. For
example, physical overactivity in children could be
replaced in adulthood by constant mental activity, feel-
ings of restlessness and difficulty engaging in sedentary
activities. Furthermore a range of characteristics closely
associated with the core ADHD syndrome often lead to
some of the impairments typically seen in adults with
ADHD. These include symptoms such as disorganiza-
tion, short-fuse, temper, mood lability and sensitivity to
stress [35,116]. Assessment of symptoms is further com-
plicated by the fact that adults have more ways to adapt
and/or compensate for problems with attention, hyper-
activity and impulsivity. For example adults with high
IQ, high socio-economic status or lower levels of
comorbid disorders may have better compensatory
strategies.
Another difference in the evaluation of ADHD in
adults is the usual reliance on self-report of symptoms
rather than informant accounts of behaviour by parents
and teachers. Although the validity of a retrospective
diagnosis of ADHD in adults may be questioned in
some cases, this is also true for other psychiatric
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diagnoses that are dependent on descriptions of current
and past behaviour. Self-reports of past and current
symptoms can however be reliable if the patient has
good insight into the condition [177]. Nevertheless, cau-
tion is needed as retrospective recall of childhood symp-
toms may be compromised in adults with ADHD, with
under reporting found to be a common problem due to
difficulties with accurate recall [9,178]. While a diagno-
sis based only on self-report is possible, such an
approach may lead to underdiagnosis of ADHD and it
may be more reliable to use information from infor-
mants as well [179]. Reliance on self-report alone may
also risk over diagnosis in some cases, but until now, no
evidence has emerged that this is the case [180]. For
these reasons it is recommended that whenever possible
corroborating information is obtained from a living par-
ent of older relative for childhood behaviour and a part-
ner, relative or close friend for current behaviour and
symptoms.
Another important criterion to evaluate is the age of
onset. The DSM-IV criterion that some symptoms and
impairment should be evident before the age of 7 years
is difficult to assess accurately in a retrospective diag-
nostic assessment in adults. In fact, research has failed
to validate to this criterion since it has been found that
the clinical syndrome that defines ADHD has similar
clinical predictions in terms of course, treatment
response and associated impairments regardless of
whether symptoms with impairment started before the
age of 7 years or later [181-187]. This may be particu-
larly important in relation to the inattentive type which
is characterised by a later onset of impairment
[172,174,188], as the inattentive symptoms may have
been missed in the pre-school years and impairment
may not have been noticed or reported until the age of
secondary school.
A further problem is recall bias by parents, since after
decades they may not accurately recall when symptoms
or impairments started. Recent evidence found that on
average parents typically report a later age of onset by
around 5-years, even where earlier age of onset was
known from previous health care records [170,189,190].
One approach to circumvent these problems is to refer
to school reports which may provide more accurate and
relevant information with respect to the age of onset.
For these reasons it is proposed to use a broader onset
criterion, up to early to mid adolescence [186,191] and
this approach has been recommended in the recent
National Institute of Health and Clinical Excellence in
the UK [32]. Clinical judgement should be used in mak-
ing the diagnosis if symptoms before the age of 7-years
cannot be recalled. In most cases a clear report of at
least some symptoms associated with impairment is
expected by early to mid-adolescence. However, even if
there is no clear recall of childhood symptoms, ADHD
should be considered when the typical syndrome that
defines ADHD is present and there is evidence of life-
time persistence of symptoms indicative of ADHD and
associated impairments. This may for instance, be the
case in some inattentive but talented people in whom
high general cognitive ability and a structured environ-
ment may have helped them to cope during childhood
and adolescence. The problem of inattention may
remain unrecognised until they tried to live indepen-
dently from their parents and were faced with the orga-
nisational and attentional demands of higher education
or employment [192].
In addition to the evaluation of symptoms, another
important criterion for the clinical diagnosis of ADHD
is the presence of significant levels of impairment asso-
ciated with the symptoms. This is critical because the
symptoms of ADHD are found to be continuously dis-
tributed throughout the population and there is no nat-
ural boundary between affected and unaffected
individuals [193]. As with symptoms of anxiety and
depression, ADHD symptoms are experienced by most
people at times. The disorder is therefore distinguished
from the normal range by the severity (extreme nature)
and persistence of symptoms, and their association with
significant levels of impairment and risk for the devel-
opment of co-occurring disorders. Criteria relate in part
to cultural expectations and this may explain why diag-
nostic and treatment rates of ADHD are higher in the
US than many European countries. From a mental
health perspective it is however important to define the
impairments from ADHD at a level that most people
would consider needs some form of medical, psycholo-
gical or educational intervention and represents a men-
tal health problem [32]. Furthermore, the diagnosis
should not be applied to justify the use of stimulant
medication to enhance performance in the absence of a
wider range of significant impairments indicating a
mental health disorder. Impairments include problems
with the following: self-esteem, personal distress from
the symptoms, social interactions and relationships,
behavioural problems, and the development of comor-
bid psychiatric syndromes.
Current evidence clearly defines ADHD as a clinical syn-
drome associated with impairments in multiple domains
including academic difficulties, impaired family relation-
ships, social difficulties and increased rates of conduct pro-
blems. In adults with ADHD increased rates of antisocial,
drug use, mood and anxiety disorders are reported in both
cross-sectional and longitudinal follow-up studies; in addi-
tion to increased rates of unemployment, poor work per-
formance, lower educational performance, increased rates
of traffic violations and accidents and criminal convictions:
reviewed in NICE, [32].
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Finally, the high familial risk among first degree rela-
tives, in the order of 20% or more [20,194], means that
a strong predictor for the ADHD in adults is having a
parent, sibling or child with ADHD. Family history of
ADHD should therefore raise the index of suspicion and
provides further supportive evidence when evaluating
individuals for ADHD.
The assessment process
Diagnosis is based on a careful and systematic assessment
of a lifetime history of symptoms and impairment. It is
not just based on a single clinical impression gained dur-
ing consultation. Central to this process is the assessment
of childhood-onset, current symptoms of ADHD and the
presence of symptoms and impairment in at least two
domains (school, work, home, interpersonal contacts).
Associated features should be evaluated including mood
lability, temper outbursts and comorbid disorders (see
differential diagnosis). It is important to take a full medi-
cal history of psychiatric and somatic treatments, as well
as a family history of psychiatric and neurological pro-
blems. It is useful to ask the patient about the pattern of
symptoms, typical of ADHD and its co-morbidities in
his/her family, taking into account familial factors and
the high heritability of the symptoms. Patterns of comor-
bidity in children and adults with ADHD have been iden-
tified and include: mood, anxiety, sleep, conduct and
substance use disorders as well as personality disorders.
Some care must be taken to distinguish between symp-
toms that often co-occur with the core syndrome of
ADHD (e.g. mood instability, ceaseless mental activity,
avoiding situations such as waiting in lines when frustra-
tion may occur) from those of a separate comorbid con-
dition (e.g. bipolar disorder, major depression, anxiety,
personality disorder). Comorbidity being the rule rather
than the exception, the evaluation of co-occurring symp-
toms, syndromes and disorders must always be part of
the clinical assessment of adult ADHD [148,150].
ADHD is also associated with increased rates of neu-
rodevelopmental traits and disorders including autism
spectrum disorder [195], dyslexia [196] and impaired
motor coordination [197]; which are thought to arise
from overlapping genetic influences. Such neurodevelop-
mental comorbidities are less well studied in adults with
ADHD, but they are commonly observed in clinical
practice and may lead to continued impairments follow-
ing successful treatment of ADHD symptoms with med-
ication. It has also been the practice in some European
countries to look for soft neurological signs during the
assessment of adult ADHD, in analogy with the diagno-
sis of DAMP in childhood (Deficits in Attention, Motor
control and Perception), that often accompanies ADHD
[198,199]. However there is limited data on the DAMP
syndrome in adults.
Comorbid substance use disorder (SUD) deserves spe-
cial attention due to the high rates of ADHD within
SUD populations. A bidirectional link between ADHD
and SUD is reported [142,200] with ADHD symptoms
over represented in SUD populations [201] and SUD in
ADHD populations [202]. From twenty five published
studies that screened for substance misuse in ADHD
samples prevalence was estimated to be around 45% to
55%. Alcohol and cannabis are the most frequently
abused substances in these populations [201] followed
by lower rates of cocaine and amphetamine abuse [203].
In contrast, from ten studies that screened for undiag-
nosed ADHD in SUD populations estimates of ADHD
ranged from 11% [204] to 54% [205]. The causes for
such comorbidity are likely to be complex including
altered reward processing in ADHD, increased exposure
to psychosocial risk factors and self treatment. Some-
times patients with ADHD describe self-treatment with
unprescribed stimulants, such as parents trying their
child’s medication. In some other cases, paradoxical
reactions to drugs of abuse are reported by patients who
feel calmer, better able to concentrate and are less
impulsive. While consuming drugs with a stimulant
action such as cocaine or amphetamine is described in a
few cases, it is more common for adults to describe a
general reduction in symptoms from alcohol and canna-
bis [206,207].
Although there are many challenges in identifying
undiagnosed ADHD in SUD settings, systematic screen-
ing is feasible [208]. This is particularly important since
SUD patients with comorbid ADHD often present with
severe forms of SUD [209] characterised by early onset,
extended duration of SUD, greater impairment and a
shorter transition from substance use to dependence
[172]. ADHD has been found to increase suicide risk in
SUD adolescents [210]. In SUD treatment outcomes,
methadone maintenance patients in the USA with sig-
nificant ADHD symptoms in the two weeks prior to
admission were less likely to achieve abstinence [211].
Close supervision is advised when treating ADHD
patients with SUD with stimulants and in cases where
diversion or abuse is a particular concern, atomoxetine
may be selected as the first line treatment. Research in
ADHD populations suggests that only a small minority
divert or misuse their medication [212] and certain long
acting formulations with a low abuse potential can be
used, although studies of adolescents suggest that 75%
of patients who do misuse medication have comorbid
SUDs [213].
Instruments for screening and diagnosis
There are many screening instruments and diagnostic
interviews available, some of which have been translated
into different languages. Commonly used rating scales
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for screening include the ADHD Rating Scale, based on
the DSM-IV criteria [214], and the six item World
Health Organisation Adult ADHD Self-Report Scale
(ASRS) Symptom Checklist (online available without
limitation and in many different languages at http://
www.hcp.med.harvard.edu/ncs/asrs.php [215]. The ASRS
includes questions for each of the 18 DSM-IV items, re-
worded to better represent the presentation of the
ADHD items in adults. The 6-item short version was
selected on the basis of sequential logistic regression, to
optimize concordance with the clinical classification;
and was estimated to have a sensitivity of 68.7% and
specificity of 99.5% with total classification accuracy of
97.9%, evaluated using population survey data [216].
Specificity of this and other screening tools may be
lower within clinical samples with high rates of other
mental health disorders; and positive screens should
always be followed by full diagnostic evaluations based
on clinical interview data. The ASRS, for example, has
been investigated in a sample with substance use disor-
ders and the sensitivity found to be higher (87.5%) and
specificity lower (68.6%) than that reported in the pre-
vious study [217].
To guide the diagnostic assessment process, other self-
report questionnaires are available, such as the Brown
ADD Scale Diagnostic Form (BADDS) [39] that mea-
sures only behaviours relating to executive functioning
and inattention; the Conners’ Adult ADHD Rating Scale
that includes the DSM-IV criteria and has different ver-
sions for patients and for significant others (CAARS)
[218]; and the Wender Utah Rating Scale (WURS) [219]
that includes also symptoms of other, often comorbid
disorders [220]. The total symptom scores of the ADHD
Rating Scale and the CAARS may be used to screen for
ADHD and to evaluate treatment outcome.
For the main diagnostic assessment use of a structured
diagnostic interview is advised, such as the Conners
Adult ADHD Diagnostic Interview for DSM-IV (CAA-
DID) [221]. An alternative under development is the
Diagnostic Interview for ADHD in adults (DIVA) [222].
Although several of the rating scales and interviews are
available in different languages there is a need for vali-
dating these translations for use throughout Europe.
Currently there are no neurobiological or neuropsy-
chological tests for ADHD with sufficient sensitivity and
specificity to serve as an individual diagnostic test [223].
Functional imaging seems promising although more
research is needed to establish its value [224-226]. Neu-
ropsychological tests (e.g. the CANTAB tests, the Stop
Signal Reaction Time, IQ or computerized tests of
executive functions and speeded reaction time
responses) may complement diagnostic assessments and
can provide an objective index of cognitive functions in
the patient with ADHD [227]. There is a recent surge in
interest in the use of cognitive-electrophysiology that
may provide data that is more sensitive to the diagnosis
than cognitive-performance data alone [228,229].
Patients with ADHD may suffer additional cognitive def-
icits, which may contribute to functional impairment,
such as in learning, reading, writing difficulties, in addi-
tion to impairments related to the autistic traits. As
there are no established norms for learning disorders in
adults, it may be difficult to distinguish these disorders
from ADHD-related learning deficits. Further research is
required to provide a full understanding of the cognitive
impairments associated with ADHD in adults.
Despite the poor predictive value of cognitive perfor-
mance tests, some experts conceptualise ADHD as pri-
marily a deficit of executive functions. While this may
not always be seen in cognitive performance deficits,
impairments are usually seen in the way that people
with ADHD manage daily tasks [175,176]. Many pro-
blems reported by adults with ADHD are thought to
reflect executive dysfunctions, including impaired self-
organisation, attentional and emotional regulation, sus-
tained effort and alertness; that may only been seen in
performance deficits in every day life and not under test
conditions. This has led to efforts to provide more sen-
sitive behavioural descriptions of performance deficits
seen in ADHD that in general reflect problems of self-
control and self-regulation [230]. These new studies are
likely to lead to improved and more sensitive symptom
and behavioural checklists for ADHD in adults.
Differential diagnosis
It is important for the diagnosis of ADHD, as well as
the correct targeting of treatments, to identify comorbid
conditions such as mood, anxiety, psychotic, organic
and substance use disorders; in addition to personality,
tic and autistic spectrum disorders. Because adults with
ADHD often exhibit low self-esteem, low mood, affec-
tive lability and irritability, these symptoms may some-
times be confused with dysthymia, cyclothymia or
bipolar disorder and with borderline personality disor-
der. Furthermore daily mood changes in ADHD are very
common, and represent a poorly regulated but essen-
tially normal range of moods, rather than the more
severe extremes of depression and elation seen in bipo-
lar disorder; and it is argued that chronic mood instabil-
ity should be considered part of the core syndrome of
ADHD [118,175,231].
ADHD and borderline personality disorder seem to
share impulsivity, affective instability, anger outbursts
and feelings of boredom [35,117,218]. In the ADHD
patient, impulsivity and anger is usually short-lived and
thoughtless, rather than driven; conflict relationships,
suicidal preoccupation, self-mutilation, identity distur-
bances and feelings of abandonment are usually less
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intense than in borderline personality disorder. How-
ever, the differences may not be clear-cut because in
both disorders symptoms are chronic and trait-like.
Importantly, individuals presenting with a diagnosis of
personality disorder who present with the ADHD syn-
drome that started in childhood will in many cases ben-
efit from pharmacological treatments for ADHD
[232,233]. Recent trials in ADHD patients indicate that
besides ADHD symptoms, mood instability improves
with both stimulant treatment and atomoxetine
[234,235]. As the order of treatment will depend on the
presence of and severity of co-morbidities, evaluation of
co-morbid disorders is a key component of the ADHD
assessment using appropriate clinical diagnostic
approaches.
How to treat adults with ADHD
Effective treatments
The symptoms of ADHD can be treated effectively in
both children and adults. The beneficial effects of stimu-
lant medication and atomoxetine on the core symptoms
of ADHD have been demonstrated in numerous studies
in children. An increasing number of studies in adults
demonstrate a similar clinical response to that seen in
children [32,236-239]. Due to the demands and respon-
sibilities of adult life, adults face many problems that are
different from those faced by children and they there-
fore need a different range of psychosocial and psycho-
logical treatments tailored to both their developmental
level and ADHD. Psychological treatments in the form
of psychoeducation, cognitive behaviour therapy, sup-
portive coaching or assistance with organising daily
activities are all thought to be effective [240-242].
Further research is however needed as there is an insuf-
ficient evidence base to recommend their routine use in
clinical practice [32].
Impact of non-treatment
Long-term follow-up, epidemiological and clinical studies
have shown that adults with untreated ADHD, when
compared to normal controls, experience higher rates of
academic failure, low occupational status, increased risk
of substance use disorders (tobacco, alcohol or drugs),
accidents and delinquency, and have fewer social rela-
tionships or friends [18,121,127,131,243,244]. Patients
diagnosed with ADHD in adulthood often complain that
they did not receive treatment earlier in life and feel that
their life would have been different if they had. Appropri-
ate treatment could have prevented accidents and
ongoing impairment at school, at work and in their peer
and partner relationships. After decades of undiagnosed
and unmet needs, the diagnosis offers an explanation for
their problems which is valuable to a lot of patients and
their family. Treatment of adult ADHD can influence
psychosocial impairment that results as a consequence of
‘core’ ADHD symptoms, and may lead to improvements
in associated features and comorbid disorders [245-247].
These include the following:
• psychological functioning and self-confidence
• family/relationship functioning
• interpersonal (broader than family) functioning
• professional/academic functioning
• cognitive deficits
• driving performance
• risk of substance use disorders
Optimal treatment algorithm
Similar to the treatment of ADHD in children, a multi-
modal approach to treatment of adults with ADHD and
associated co-morbid disorders should be taken [248].
Ideally, the treatment plan would also involve the adult’s
partner, family or close relationships. The multimodal
approach includes:
• psycho-education of ADHD and comorbid
disorders
• pharmacotherapy for ADHD and comorbid
disorders
• coaching
• cognitive behaviour psychotherapy (individual and
group)
• family therapy
Treatment focus in co-morbid ADHD
Treatment should follow careful diagnostic assessment of
ADHD and associated comorbid disorders. In the case of
comorbidity, the integrated treatment plan should address
both ADHD and the comorbid condition, the order of
pharmacological treatment depending on the type and
severity of comorbidity. Generally, severe mental health
disorders should be treated first, such as in-patients with
psychosis, major depression, mania or drug addiction; fol-
lowing which the diagnosis of ADHD and need for treat-
ment can be reviewed. However, treatment of milder
depressive and anxiety disorders may be deferred until
after treatment of ADHD and often needs no further treat-
ment as the comorbid symptoms may resolve following
effective treatment of ADHD. Symptoms such as demora-
lisation and low self-esteem following a life with ADHD,
and mood instability, improve with stimulant treatment
alone [234]. It is up to the clinician to decide on what is
the most important need for every patient with specialist
advice being sort for more complex cases.
With respect to substance use disorders, ADHD is
considered an important factor in its aetiology as the
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substances are often used for self-medication and may
relieve symptoms like restlessness, inattention, impulsiv-
ity and sleep problems [207,249-251]; or may be taken
as part of stimulus seeking (novelty seeking) traits that
are also associated with ADHD. In such cases, treatment
of ADHD may help patients to stop substance use for
self-medication [252-254] or may reduce impulsive sti-
mulus seeking behaviour. However, systematic research
has not provided a strong evidence base for appreciable
improvements in ADHD when treated in the presence
of substance use disorders [255,256]; and drug or alco-
hol abuse disorders should always be targeted as a pri-
mary disorder. Treating ADHD in parallel with SUD
can however be important in some cases, particularly
where ADHD is severe or where there is good under-
standing and compliance for the treatment program.
However, in some countries, regulatory rules will not
allow prescription of stimulants in patients with sub-
stance use disorders. Patients should be asked to register
their drug/substance intake and be encouraged to stop
their use. Despite concerns that pharmacotherapy with
stimulant medication may be a risk factor for substance
abuse, the literature supports the view that stimulant
treatment for ADHD either has no impact in risk for
substance abuse, or may even lower the risk of sub-
stance abuse by reducing the early onset of substance
abuse in adolescents [206,254,257-259].
Psycho-education
Psycho-education is the first step in the treatment plan
and involves educating the patient and ideally also the
partner or family about ADHD symptoms and impair-
ment, the prevalence in children and adults, the fre-
quent comorbidity, the heritability, the brain
dysfunctions involved, as well as the treatment options.
In many cases, simply providing the patient with this
information may help the patient’s understanding and
bring him or her comfort. Often this process offers new
insights into past difficulties. Relationship difficulties
often decline after this sharing of information with
family members. Feelings of guilt and remorse can be
left behind, and the patient’s social network may begin
to be restored. This social network will prove invaluable
to the patient during the treatment process. Informing
the patient about the existence of self-help groups may
be valuable, allowing him or her to join and share infor-
mation and experiences, as well as to gain further com-
fort and understanding. There is a need to further
develop structured psychoeducation programs with spe-
cific objectives.
Pharmacotherapy for adult ADHD in Europe
Stimulants (methylphenidate and dexamphetamine) are
first choice medication treatments for ADHD in
children and adults, based on an extensive and still
growing body of data concerning efficacy and safety
[32,260]. Atomoxetine is usually considered the second
line treatment, followed by other non-stimulants like
bupropion, guanfacine, modafinil and tricyclic antide-
pressents, based on efficacy outcomes in controlled stu-
dies in different age groups [239,261-264].
Stimulants are effective in about 70% of patients with
ADHD in controlled studies [265-267] depending on the
study design and maximum drug dosage. A recent Eur-
opean study of adults with ADHD showed the effective-
ness of methylphenidate over a period of six months, in
the longest double blind placebo controlled trial to date
[268]. Stimulant treatment not only improves the symp-
toms and impairing behaviours associated with ADHD,
but also improves related problems such as low self-
esteem, anger outbursts, mood swings, cognitive pro-
blems and social and family function. Side-effects are
usually mild and transitory, mainly consisting of head-
ache, reduced appetite, palpitations, nervousness, diffi-
culty falling asleep, and dry mouth [148,269,270].
Stimulants may increase blood pressure and heart rate,
and decrease weight, therefore patients should be
assessed regarding these issues prior to, and monitored
during treatment. Stimulants are not advised during
pregnancy or breastfeeding and are contraindicated in
psychotic disorders up to now; although some specialists
have treated ADHD successfully in stable patients with
schizophrenia maintained on antipsychotics [271]. Rela-
tive contra-indications are hypertension, cardiac pro-
blems including angina, hypertrophic cardiomyopathy
and arrhythmias, hyperthyroidism and glaucoma. For
these disorders, first referral to and treatment by a spe-
cialist are needed before starting a stimulant. Stimulants
may be used in autism with generally positive effects,
although in some cases autistic features may worsen
[272-275]. A recent meta-analysis indicated that treating
ADHD in children with tic disorders is safe and effective
[276,277]. Stimulants have little impact on seizure
threshold and may be used in epilepsy [278].
Although stimulants are by far the best studied and
most effective treatment for ADHD, their use in some
parts of Europe is still controversial in both children
and adults. It is not yet common practice for doctors to
prescribe stimulant medication to adults. As a result
support services and expertise for treating ADHD in
adults are not always available. As discussed earlier, the
use of stimulants continues to be hampered by stigma
and lack of up to date information in their use, with
restricted access in many European countries [279].
The hesitancy and uncertainty about the appropriate
use stimulant medication by both the general public and
many physicians may also be related to the history of
abuse with amphetamines in the past. Health authorities
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have given methylphenidate the same drug classification
as amphetamines and they both perform similar to each
other in traditional assays of abuse [280,281]. Abuse
potential has been studied by Nora Volkow (Director of
the National Institute of Drug Abuse, USA) who showed
that abuse potential relates to the route of administra-
tion, with rapid rise in dopamine levels following injec-
tion or snorting of stimulants. In contrast, during oral
clinical use, methylphenidate elicits slow steady-state
dopamine increases in the brain which mimic those of
tonic neuron firing, rather than rapid dopamine changes
associated with reinforcing drug-like effects [257]. In the
Volkow study it was found that intravenous methylphe-
nidate could not be distinguished from cocaine by
cocaine addicts, whereas this was not the case for oral
methylphenidate. Therefore the use of extended release
medications that have a slow rate of serum rise, are pre-
ferable to reduce potential for abuse and diversion.
Importantly, both clinical studies and clinical experi-
ence support the view that the methylphenidate does
not lead to stimulant or drug addictions. On the con-
trary, it has been shown to have a neutral or reducing
impact on substance abuse and the risk of relapse
[206,253,254]. Furthermore, stimulants are not addictive
from the clinical perspective. Adolescents treated from
childhood generally use less stimulant medication or
stop, using instead of taking more. A common problem
is poor compliance or cessation of treatment during the
adolescent years. There is also no clear evidence of tol-
erance over time. Neither has stimulant use been asso-
ciated with adverse effects on driving, but rather is
associated with an improvement in the concentration of
ADHD patients during driving [127,282]. The main
potential problem associated with their use and reported
in a number of studies from the US is the inappropriate
diversion of stimulants, by parents self-treating them-
selves with their children’s medication or as a cognitive
enhancement medication for college students. This
should not however detract from their specific use to
reduce ADHD symptoms and associated impairments in
people with ADHD [283].
Continued research in adult patients and education
about efficacy and safety may help to overcome these
problems. The non stimulant atomoxetine may be an
alternative to treatment with stimulants in substance
abuse patients with ADHD, although studies showing
superiority over stimulants in this difficult patient popu-
lation are still lacking [200,284-286].
Types of stimulants
In the United States, more than ten different stimulant
preparations have been developed for treatment of
ADHD, the most recent being long acting formulations
of oros-methylphenidate, mixed amphetamine salts,
dexmethylphenidate and lis-dexamphetamine
[265,287,288]. These improvements were necessary
because of the very short half-life leading to relatively
short duration of symptom control from immediate
release methylphenidate (two to four hours) and dexam-
phetamine (three to five hours). The requirement for a
longer duration of activity in adults, requires repetitive
dosing with immediate release stimulants, of between
three to four doses in most cases, and more often in
others, to avoid rebound symptoms and for adequate
control of ADHD symptoms during the day and evening
[148,270]. Compliance to such frequent dosing regimens
is however poor in ADHD patients due to forgetfulness,
inattentiveness and self-organisation problems, leading
to daily instability by frequent rebound symptoms and
ineffective treatment [148,289-291].
Extended release preparations of stimulants have dura-
tions of action between 6 to 14 hours, which may per-
mit once-daily dosing, although an adult may still need
twice daily dosing of medication for a 12-16 hour day.
Currently, combinations of immediate and extended
release preparations are often prescribed in adults with
the aim of tailoring the dose regime to the individual
requirement and medication response of each patient.
Dosing schemes and maximum daily dose vary across
Europe (from 0.3-1.5 mg of methylphenidate/kg/day).
However, the panel recommends that the dose of stimu-
lants in adults should be individually adjusted, based on
response and tolerability. The short half life of the medi-
cations suggest that it is more practical to consider
maximum dose in terms of the maximum taken at each
time point, the length of the effect of each dose on the
control of ADHD symptoms, and the number of doses
required to provide symptom control throughout the
day; rather than a maximum based only on mg/kg per
day. Individual differences in the optimal dose response
to stimulant medication means that the best approach is
to titrate the dose for each individual, starting at a low
dose and increasing to an effective dose, while keeping
side effects to a minimum; and should not be deter-
mined on a mg/kg basis.
In Europe, limited and different products are regis-
tered in the various countries. Some countries still only
have access to immediate release methylphenidate and
may or may not have access to dexamphetamine, while
increasingly the longer-acting extended release prepara-
tions are being introduced. In Switzerland Dexmethyl-
phenidate XR was licensed for use in adults in 2009 and
this has been reported as a safe and effective option
[292].
Second line pharmacotherapeutic treatments
For adults with ADHD who do not respond to stimulant
therapy or who have a condition in which a stimulant is
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contraindicated, the non-stimulant atomoxetine that is
licensed for child and adult ADHD in the USA is an
appropriate alternative [247]. Atomoxetine has an effect
size of around 0.4 in adults [32,293], a duration of
action of 24 hours, and no abuse potential [294]. Ato-
moxetine may be indicated in patients with comorbid
substance use disorders, emotional dysregulation or
social anxiety [295-297]. Other choices comprise medi-
cations like long acting bupropion, modafinil and guan-
facine, that have all been investigated in ADHD
[262,298-300]. Tricyclic antidepressants like Desipra-
mine, an imipramine metabolite, has been shown to be
effective in adults with ADHD [301]. However, these
medications must be considered fourth line agents due
to their side effects, limited value in treating the symp-
toms of inattention and relatively low effect size com-
pared to stimulants in the treatment of ADHD [302].
In more complicated co-morbid cases, clinical experi-
ence indicates that treatment may be combined with
antidepressants and mood stabilizers, although con-
trolled studies are still lacking [303]. A recent review on
drug interactions in the treatment of ADHD concluded
that methylphenidate appears to be more implicated in
pharmacokinetic interactions suggestive of possible
metabolic inhibition, while amphetamine was more
involved in pharmacodynamic interactions and could
potentially be influenced by medications affecting cyto-
chrome P450 (CYP2D6) [304]. Only monoamine oxidase
inhibitors (MAOIs) are contradicted with the concomi-
tant use of stimulants. Other drugs such as antidepres-
sants and antipsychotics can be given at the same time
as stimulants but in a few cases some adjustment in the
dose of either drug might be required. Finally, there is
no consistent evidence from randomised control trials
for the use of food supplements, such as omega-3 fatty
acids ADHD [305].
Coaching and Cognitive Behavioural Therapy
Pharmacotherapy alone is usually not sufficient to stabi-
lise the many problems of adults with ADHD. Coaching
provides a structured, supportive therapy, either indivi-
dually or in group sessions. Coaching aims to teach pro-
blem-solving skills for identified practical problems. Due
to a lifetime history of the impairment, adults with
ADHD have typically not learnt practical organisational
skills [306,307] and may have developed poor coping
skills and inappropriate behaviours in response to the
impairments associated with ADHD.
A coaching program may include:
• acceptance of the disorder
• learning to deal with time management
• learning to limit activities to ‘one goal at a time’
• organising home, administration, finances
• dealing with relationship and work difficulties
• learning to initiate and complete tasks
• understanding emotional responses associated with
ADHD
These components of coaching are also addressed by
cognitive behavioural therapy for adult ADHD
[241,308]. According to the clinical experience of the
panel, many adults may benefit from supportive and/or
cognitive behavioural therapy in combination with phar-
macotherapy. Other forms of psycho-social or family
therapy may help with impairments associated with
ADHD, such as relationship problems and low self-
esteem [309]. Psychotherapy targets the adaptation of
the ADHD patient to a lifelong debilitating disorder and
it may relieve co-morbid symptoms.
Current research does not support the efficacy of psy-
chotherapeutic treatments as sole treatment for adult
ADHD; neither do they relieve the core symptoms of
ADHD. They are however considered an import adjunc-
tive treatment for people who prefer a psychological
approach or where residual symptoms or comorbidities
remain. CBT has a strong evidence base for the treat-
ment of some of the comorbidities associated with
ADHD yet there are few controlled trials in adults with
ADHD. The findings in ADHD are reviewed by the
Research Forum on Psychological Treatments for Adults
with ADHD, who identified moderate to large effect
sizes from five empirical studies. They concluded that
psychological treatments may play a critical role in the
management of adults with ADHD who are motivated
and developmentally ready to acquire new skills as
symptoms remit [310]. Safren and colleagues [241] com-
pared CBT plus medication with medication treatment
alone and found significantly greater improvements for
ADHD symptoms and anxiety and depression scores in
the combined treatment group. Similar findings were
reported by Rostain and Ramsey [247], while a further
study reported added benefits from CBT and psychoe-
ducation delivered in a brief intensive group format
[311]. Alternative strategies have focused on strengthen-
ing cortical (executive) function with several studies
indicating treatment effects in ADHD symptoms using
techniques such as working memory training and neuro-
feedback and cognitive remediation therapy in children
[312-316] and meta-cognitive training in adults [317]. A
full review of psychological approaches for ADHD
throughout the lifespan has recently be published by
Young and colleagues [240]
Prognosis and costs
ADHD in adults presents as a lifelong condition that
started during childhood. The precise details of the clin-
ical presentation may change with age and with the
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demands of adult life, but are broadly similar to those
seen in children. As medication treatment for ADHD
does not cure the disorder and some or all symptoms
may return after discontinuation of medication, long-
term pharmacological and psycho-social treatment may
be necessary. The poor long term prognosis of untreated
ADHD has implications for the costs of illness. In chil-
dren, the economic burden of ADHD has been esti-
mated to be approximately double those of normal
controls, due to substantially more inpatient as well as
outpatient hospitalisations and emergency department
visits [318]. The economic burden of untreated adult
ADHD has been increasingly studied and shows the
same pattern as in children, with higher than normal
costs of sickness leave, less productivity, more accidents
and more health care costs [141,319,320]. Effective
management of the patient with ADHD is justified from
a health economic perspective since undiagnosed and
untreated ADHD will lead to inefficient health care use,
less satisfactory clinical outcomes, lower personal well-
being and poorer social and professional interactions.
Conclusions
A summary of the main conclusions is listed in Table 1.
ADHD persists in adults in the majority of subjects with
significant psychosocial impairment and a high comor-
bidity rate leading to high levels of personal distress and
a substantial economic burden for society if left uniden-
tified and untreated. The lifetime persistence of symp-
toms and impairment of ADHD is the hallmark of this
disorder in the majority of cases. Diagnosis should
include extensive psychiatric work-up including a
Table 1 Summary of key points from the consensus statement
Neurobiological and
environmental background
• Anomalies in brain functioning identified in case control studies of cognitive, electrophysiological and
neuroimaging studies, and the effectiveness of pharmacological treatments with dopamine agonists support
the neurobiological underpinnings of ADHD.
• High heritability and associated environmental risk factors suggest a primary role for genetic influences that
are moderated by environmental factors in the majority of cases.
Diagnosis • The gender differences in child and adult ADHD may be due to different expression of symptoms and co-
morbidities, perception of impairments, and referral bias; and deserve further study.
• Age, gender, and IQ matched reference values are still lacking for diagnostic assessment of ADHD in adults.
• The age-of-onset criteria required for the retrospective diagnosis of ADHD in adults is less reliable and less
important than the persistence of symptoms and impairment of ADHD during the lifespan.
• A cut off of 4/9 current DSM-IV criteria may be sufficient in adults with a childhood onset of symptoms,
when accompanied by significant impairments.
• Age-appropriate presentations of ADHD symptoms should be taken into account when scoring the
symptoms of ADHD in adults.
• The diagnosis of ADHD in adulthood should be based on self-report and in-depth evaluation, but collateral
information is desirable.
• Various instruments are available for screening and assessment of ADHD, but validation studies are urgently
needed.
• Neurobiological and neuropsychological tests are neither imperative nor sufficient for the diagnosis of
ADHD but may document specific functional impairments.
Treatment • Non- treatment may deprive the patient of the chance to resolve functional and psychosocial impairments
at personal, relationship and professional levels.
• The severity of ADHD and associated co-morbid disorders should be the first guide to select which
disorder to treat first. Treatments can often be combined.
• Albeit local regulatory rules may dictate differently, in patients with ADHD and substance use disorder,
ADHD treatment with stimulants should not be withheld, but rather postponed until problematic substance
use is stopped and there is a commitment to the treatment process.
• Stimulants are the treatment of choice for adults with ADHD. Long-lasting, extended release formulations
are preferred for reasons of adherence to treatment, for the protection against abuse, to avoid rebound
symptoms, for safer driving, and to provide cover throughout the day without the need for multiple dosing.
• The non-stimulant atomoxetine can be a second line treatment. Others like modafinil, bupropion,
guanfacine, and tricyclic antidepressants have shown efficacy in controlled studies.
• Psychotherapy targets the relief of co-morbidities and behavioural, social, cognitive or other functional
impairments.
• The poor long-term prognosis in a substantial part of patients and the absence of a cure upon stopping
medication underline the role of long-term management of the adult with ADHD.
• With appropriate diagnosis and treatment, morbidity may be low, health care use efficient, outcomes better
and associated with lower economic burden.
• More research on ADHD throughout the lifespan until old age is needed.
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detailed account of the developmental history, both cur-
rent and retrospective account of ADHD symptoms and
impairment and associated co-morbidities, before start-
ing treatment. To prevent underreporting of symptoms,
external validation is desirable by collecting information
from relevant informants. The panel recommends multi-
modal treatment, comprising of psychoeducation, phar-
macotherapy, coaching and/or cognitive behavioural
therapy; and ideally involving the adult patient’s partner,
family or close friends. Diagnostic and treatment ser-
vices for adult ADHD should be established throughout
Europe. European research into adult ADHD should be
further developed in order to provide a better under-
standing of the way that ADHD presents from child-
hood until old age, to differentiate ADHD from
common comorbidities and to improve treatment
options.
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